Respiratory Antiviral Treatment Industry Size to Reach US$ 5.3 Billion and Growing at ~6% CAGR By 2030

According to the report, the global respiratory antiviral treatment market was valued at US$ 2.9 Bn in 2019 and to cross valuation of US$ 5.3 Bn by 2030 at a CAGR of ~6% from 2020 to 2030. Antiviral drugs are therapeutics that prevent the development and replication of virus without affecting host cells. These drugs do not destroy their target virus, as it is an obligatory intracellular parasite. Instead, these inhibit their propagation by deactivating the viral enzymes. Different types of drugs are used in the treatment of respiratory viral diseases including ribavirin, aciclovir, oseltamivir, zanamivir amantadine, and amantadine. The growth of the global respiratory antiviral treatment market can be ascribed to rise in prevalence of respiratory viral diseases and ongoing clinical trials, and increase in FDA approvals.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐈𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞) - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=77000

𝐎𝐮𝐭𝐛𝐫𝐞𝐚𝐤 𝐨𝐟 𝐏𝐚𝐧𝐝𝐞𝐦𝐢𝐜 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐕𝐢𝐫𝐚𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬, 𝐎𝐧𝐠𝐨𝐢𝐧𝐠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬, 𝐚𝐧𝐝 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐢𝐧 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐭𝐨 𝐃𝐫𝐢𝐯𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭

The rise in prevalence and incidence of respiratory viral diseases such as influenza and bronchiolitis across the globe is a key factor driving the global respiratory antiviral treatment market. The WHO estimated that around 3 million to 5 million influenza cases occur globally every year; 250,000 to 500,000 of these result in deaths. Hence, increase in incidence of influenza continues to encourage the use of influenza medication, thereby driving the market. According to the CDC, COVID-19 pandemic resulted in over 814,000 deaths globally, as of August 2020.

Ongoing clinical trials for respiratory viral disease treatment, drugs, pipeline products, and safety and efficacy studies have increased over the past few years. Moreover, marketing approvals for antiviral therapies and drugs by the FDA and other authorities in different regions are expected to boost the growth of the global respiratory antiviral treatment market. In October 2019, Genentech, Inc. received the U.S. Food and Drug Administration (FDA) approved for Xofluza (Baloxavir Marboxil) for people at high risk of developing influenza-related complications.

𝐍𝐞𝐮𝐫𝐚𝐦𝐢𝐧𝐢𝐝𝐚𝐬𝐞 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 𝐭𝐨 𝐃𝐨𝐦𝐢𝐧𝐚𝐭𝐞 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐀𝐧𝐭𝐢𝐯𝐢𝐫𝐚𝐥 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭

In terms of drug class, the global respiratory antiviral treatment market has been divided into nucleoside analogs, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors. The neuraminidase inhibitors segment dominated the global respiratory antiviral treatment market in 2019. This trend is likely to continue during the forecast period. Oseltamivir is first-line treatment for several respiratory viral diseases such as influenza. It is available as a prodrug oseltamivir phosphate and is converted by the liver to active metabolite oseltamivir carboxylate. The mechanism of action of oseltamivir carboxylate and other NAIs is to interfere with the release of influenza viral particles from infected host cells by binding to influenza viral neuraminidase, resulting in reduced spread of influenza viruses in the respiratory tract. This factor is projected to drive the segment.

Nucleoside analogs was the second largest segment in terms of market share in 2019. The growth of the segment can be attributed to increase in demand for nucleoside analogs, owing to rise in occurrence of seasonal influenza and RSV infection.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 | 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭 - https://www.transparencymarketresearch.com/checkout.php?rep_id=77000<ype=S

𝐈𝐧𝐟𝐥𝐮𝐞𝐧𝐳𝐚 𝐭𝐨 𝐛𝐞 𝐌𝐚𝐢𝐧 𝐃𝐢𝐬𝐞𝐚𝐬𝐞

In terms of disease type, the global respiratory antiviral treatment market has been categorized into influenza, bronchiolitis, pneumonia, upper respiratory tract infections (URTIs), and others (measles, etc.). The influenza segment accounted for prominent share of the global respiratory antiviral treatment market in 2019, owing to rise in number of patients and awareness about the disease. According to the World Health Organization, around 1 billion influenza cases are reported globally each year, and 300,000 to 500,000 deaths occur due to influenza in every year.

𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬 𝐭𝐨 𝐛𝐞 𝐌𝐚𝐣𝐨𝐫 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥

In terms of distribution channel, the global respiratory antiviral treatment market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment led the global respiratory antiviral treatment market in terms of revenue in 2019. The trend is expected to continue during the forecast period. Rapid increase in the number of hospitals and wide range of services available in multispecialty hospitals are likely to augment the segment during the forecast period. The surge in the number of patients opting for retail pharmacies due to a large number of product brands available at discounted prices at these pharmacies is projected to drive the retail pharmacies segment during the forecast period.

𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐭𝐨 𝐃𝐨𝐦𝐢𝐧𝐚𝐭𝐞 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐀𝐧𝐭𝐢𝐯𝐢𝐫𝐚𝐥 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭

The global respiratory antiviral treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global respiratory antiviral treatment market in 2019, followed by Europe. North America's large market share can be ascribed to increase in the number of people with respiratory viral diseases, new product launches, and presence of major players in the region. According to the CDC, around 5.6 million patients are suffering from COVID-19 in the U.S., as of August 2020.

The respiratory antiviral treatment market in Asia Pacific is anticipated to expand at a high CAGR from 2020 to 2030. This can be ascribed to the presence of developing countries with commercial hubs, expanding business organizations, rise in awareness about respiratory antiviral, improving healthcare infrastructure, and increase in investments by companies in their technical aspects.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐨𝐧 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐀𝐧𝐭𝐢𝐯𝐢𝐫𝐚𝐥 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭

The global respiratory antiviral treatment market is fragmented in terms of number of players. Key players operating in the global market include F. Hoffmann-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Mylan, Inc., Merck & Co., Inc., and AstraZeneca plc.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=77000

𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐀𝐧𝐭𝐢𝐯𝐢𝐫𝐚𝐥 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐀𝐧𝐭𝐢𝐯𝐢𝐫𝐚𝐥 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐃𝐫𝐮𝐠 𝐂𝐥𝐚𝐬𝐬

𝐍𝐮𝐜𝐥𝐞𝐨𝐬𝐢𝐝𝐞 𝐀𝐧𝐚𝐥𝐨𝐠𝐬
Ribavirin
Aciclovir
Others

𝐍𝐞𝐮𝐫𝐚𝐦𝐢𝐧𝐢𝐝𝐚𝐬𝐞 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬
Oseltamivir
Zanamivir
Others

𝐈𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥 𝐁𝐥𝐨𝐜𝐤𝐞𝐫𝐬

𝐅𝐮𝐬𝐢𝐨𝐧 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬

𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐀𝐧𝐭𝐢𝐯𝐢𝐫𝐚𝐥 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐲𝐩𝐞
Influenza
Bronchiolitis
Pneumonia
Upper Respiratory Tract Infections (URTIs)
Others (measles, etc.)

𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐀𝐧𝐭𝐢𝐯𝐢𝐫𝐚𝐥 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 -

𝐃𝐢𝐬𝐢𝐧𝐟𝐞𝐜𝐭𝐚𝐧𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.globenewswire.com/news-release/2022/05/04/2436017/0/en/Disinfectants-Market-to-Expand-at-CAGR-of-7-1-During-Forecast-Period-Notes-TMR-Study.html

𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐢𝐜𝐞 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.prnewswire.com/news-releases/medical-device-technologies-market-to-expand-at-cagr-of-4-3-during-forecast-period-notes-tmr-study-301515758.html

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.